Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19 | Bennett Institute for Applied Data Science

Paper information

Authors: Angel Wong,

Brian MacKenna,

Caroline Morton,

Anna Schultze,

Alex Walker,

Krishnan Bhaskaran,

Jeremy Brown,

Christopher Rentsch,

Elizabeth Williamson,

Henry Drysdale,

Richard Croker,

Seb Bacon,

Will Hulme,

Chris Bates,

Helen Curtis,

Amir Mehrkar,

Dave Evans,

Peter Inglesby,

Jonathan Cockburn,

Helen McDonald,

Laurie Tomlinson,

Rohini Mathur,

Kevin Wing,

Harriet Forbes,

Rosalind Eggo,

John Parry,

Frank Hester,

Sam Harper,

Stephen Evans,

Liam Smeeth,

Ian Douglas,

Ben Goldacre
Citation: Wong AY, MacKenna B, Morton CE The OpenSAFELY Collaborative, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Annals of the Rheumatic Diseases 2021;80:943-951. https://doi.org/10.1136/annrheumdis-2020-219517.
DOI: 10.1136/annrheumdis-2020-219517
Preprint: OpenSAFELY: Do adults prescribed non-steroidal anti-inflammatory drugs have an increased risk of death from COVID-19?
Categories: OpenSAFELY

Abstract

Objectives

To assess the association between routinely prescribed non-steroidal anti-inflammatory drugs (NSAIDs) and deaths from COVID-19 using OpenSAFELY, a secure analytical platform.

Methods

We conducted two cohort studies from 1 March to 14 June 2020. Working on behalf of National Health Service England, we used routine clinical data in England linked to death data. In study we identified people with an NSAID prescription in the last 3 years from the general population. In study we identified people with rheumatoid arthritis/osteoarthritis. We defined exposure as current NSAID prescription within the 4 months before 1 March 2020. We used Cox regression to estimate HRs for COVID-19 related death in people currently prescribed NSAIDs, compared with those not currently prescribed NSAIDs, accounting for age, sex, comorbidities, other medications and geographical region.

Results

In study we included 536 423 current NSAID users and 1 927 284 non-users in the general population. We observed no evidence of difference in risk of COVID-19 related death associated with current use (HR 0.96, 95% CI 0.80 to 1.14) in the multivariable-adjusted model. In study we included 1 708 781 people with rheumatoid arthritis/osteoarthritis, of whom 175 495 (10%) were current NSAID users. In the multivariable-adjusted model, we observed a lower risk of COVID-19 related death (HR 0.78, 95% CI 0.64 to 0.94) associated with current use of NSAID versus non-use.

Conclusions

We found no evidence of a harmful effect of routinely prescribed NSAIDs on COVID-19 related deaths. Risks of COVID-19 do not need to influence decisions about the routine therapeutic use of NSAIDs.